Publications by authors named "E H Ka"
Predictive Efficacy of Dual Therapies Combining Integrase Strand Transfer Inhibitors with Second-Generation Non-Nucleoside Reverse Transcriptase Inhibitors Following HIV-1 Treatment Failure in Cameroon: Implications for the Use of a Long-Acting Therapeutic Strategy in Low- and Middle-Income Countries.
Viruses
November 2024
Dual therapies (DT) combining integrase strand transfer inhibitors (INSTIs) with second-generation non-nucleoside reverse transcriptase inhibitors (2nd-Gen-NNRTIs) offer new possibilities for HIV treatment to improve adherence. However, drug resistance associated mutations (RAMs) to prior antiretrovirals may jeopardize the efficacy of DT. We herein describe the predicted efficacy of DT combining INSTIs + 2nd-Gen-NNRTI following treatment failure among Cameroonian patients.
View Article and Find Full Text PDFPlasma Viral Load of 200 Copies/mL is a Suitable Threshold to Define Viral Suppression and HIV Drug Resistance Testing in Low- and Middle-Income Countries: Evidence From a Facility-Based Study in Cameroon.
J Int Assoc Provid AIDS Care
December 2024
Introduction: In low-and-middle-income-countries (LMIC), viral suppression is defined as plasma viral load (PVL) below 1000 copies/mL (low-level viremia [LLV]) and threshold for HIV drug resistance (HIVDR) testing. However, there is evidence that drug resistance mutations (DRMs) may emerge at LLV, thus compromising antiretroviral treatment (ART) response We evaluated sequencing success rates (SSR) at LLV, described HIVDR profiles and adequacy with potential efficacy of tenofovir-lamivudine-dolutegravir (TLD).
Methods: A cross-sectional study was conducted among individuals with LLV at the Chantal BIYA International Reference Centre, Yaoundé, Cameroon from January 2020 through August 2021.
HIV drug resistance following pre-exposure prophylaxis failure among key populations in sub-Saharan Africa: a systematic review and meta-analysis protocol.
Ther Adv Infect Dis
December 2024
Article Synopsis
- Key populations (KP), which are crucial in addressing HIV, represent 70% of new infections globally and are the focus of a study examining drug resistance related to PrEP failure in sub-Saharan Africa.
- The research will systematically review various studies to determine the prevalence of HIV drug resistance (HIVDR) among these populations after PrEP failure, analyzing data from diverse groups including gay men, sex workers, and people who inject drugs.
- Findings aim to identify the rates of PrEP failure and drug resistance, helping improve HIV prevention strategies and inform medical practices for effective antiretroviral use in KP within sub-Saharan Africa.
Empowering adolescents living with perinatally-acquired HIV: tailored CD4+ count assessment for optimized care, the EDCTP READY-study.
Front Med (Lausanne)
September 2024
Background: The elevated rate of AIDS-related mortality in Sub-Saharan Africa among adolescents living with HIV (ALHIV) is influenced by various factors, notably immunosuppression, within a framework of limited therapeutic alternatives. We aimed to enhance the management of pediatric HIV by assessing the immune response and associated factors in perinatally-infected ALHIV on antiretroviral therapy (ART) in Cameroon.
Methods: A cohort study was conducted from 2018-2020 among 271 ART-experienced ALHIV in Cameroon.
Evaluation of Viral Suppression in Paediatric Populations: Implications for the Transition to Dolutegravir-Based Regimens in Cameroon: The CIPHER-ADOLA Study.
Biomedicines
September 2024
Article Synopsis
- Mortality in children accounts for 15% of global AIDS-related deaths, with Cameroon facing a higher rate of 25%, mainly due to poor viral response.
- A study analyzed viral suppression (VS) among Cameroonian children and young adults receiving antiretroviral therapy (ART) to identify factors affecting VS, finding an overall rate of 82.3%.
- Key findings revealed that younger age, longer ART duration, and certain non-DTG-based regimens were independent predictors of non-VS, suggesting the need for prioritizing transition to DTG-based regimens to improve outcomes.